Cognition in patients treated with targeted therapy for chronic myeloid leukemia: a controlled comparison

References

• American Cancer Society. Cancer facts & figures 2021. Atlanta: American Cancer Society; 2021.
   Google Scholar
• Hehlmann R, Lauseker M, Saussele S, et al. Final evaluation of randomized CML-Study IV: 10-Year survival and evolution of terminal phase. Blood. 2017;130(Suppl_1):897–897.
   Google Scholar
• Giles FJ, O'Dwyer M, Swords R. Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia. 2009;23(10):1698–1707.
   PubMed Web of Science ®Google Scholar
• NCCN Guidelines for Patients. Chronic Myeloid Leukemia. Version 3. 2020.
   Google Scholar
• Bhullar KS, Lagarón NO, McGowan EM, et al. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer. 2018;17(1):48.
   Google Scholar
• Chen KK, Du TF, Xiong PS, et al. Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia With Losing Major Molecular Response as a Definition for Molecular Relapse: A Systematic Review and Meta-Analysis. Front Oncol. 2019;9:372.
   Google Scholar
• Cerveira N, Loureiro B, Bizarro S, et al. Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution. BMC Cancer. 2018;18(1):1245.
   PubMedGoogle Scholar
• Laneuville P. When to stop tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Curr Treat Options Oncol. 2018;19:15.
   PubMed Web of Science ®Google Scholar
• Hahn EA, Glendenning GA, Sorensen MV, IRIS Investigators, et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS study. J Clin Oncol. 2003;21(11):2138–2146.
   PubMed Web of Science ®Google Scholar
• Flynn KE, Atallah E. Quality of life and long term therapy in patients with chronic myeloid leukemia. Curr Hematol Malig Rep. 2016;11(2):80–85.
   PubMed Web of Science ®Google Scholar
• Phillips KM, Pinilla-Ibarz J, Sotomayor E, et al. Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer. 2013;21(4):1097–1103.
   PubMed Web of Science ®Google Scholar
• Williams LA, Gonzalez AGG, Ault P, et al. Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood. 2013;122(5):641–647.
   PubMed Web of Science ®Google Scholar
• Pemmaraju N, Kantarjian HM, Tanaka MF, et al. Memory impairment in chronic phase (CP) chronic myeloid leukemia (CML) patients (pts) treated with dasatinib tyrosine kinase inhibitor (TKI) therapy. Blood. 2011;118(21):3771–3771.
   Google Scholar
• Chamoun K, Rabinovich E, Baer L, et al. A case of neurocognitive deficit strongly related to dasatinib therapy. Hematol Transfus Cell Ther. 2020;42(1):80–82.
   PubMedGoogle Scholar
• Efficace F, Breccia M, Saussele S, et al. Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? Ann Hematol. 2012;91(9):1371–1381.
   PubMed Web of Science ®Google Scholar
• Efficace F, Baccarani M, Breccia M, et al. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia. 2013;27(7):1511–1519.
   PubMed Web of Science ®Google Scholar
• Ganz PA, Kwan L, Castellon SA, et al. Cognitive complaints after breast cancer treatments: examining the relationship with neuropsychological test performance. J Natl Cancer Inst. 2013;105(11):791–801.
   PubMedGoogle Scholar
• Pendergrass JC, Targum SD, Harrison JE. Cognitive impairment associated with cancer. Innov Clin Neurosci. 2018;15(1-2):36–44.
   PubMedGoogle Scholar
• Hoogland AI, Nelson AM, Small BJ, et al. The role of age in neurocognitive functioning among adult allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 2017;23(11):1974–1979.
   PubMed Web of Science ®Google Scholar
• Jim HSL, Small BJ, Patterson S, et al. Cognitive impairment in men treated with luteinizing hormone-releasing hormone agonists for prostate cancer: a controlled comparison. Support Care Cancer. 2010;18(1):21–27.
   PubMed Web of Science ®Google Scholar
• Gonzalez BD, Jim HSL, Booth-Jones M, et al. Course and predictors of cognitive function in patients with prostate cancer receiving Androgen-Deprivation therapy: a controlled comparison. J Clin Oncol. 2015;33(18):2021–2027.
   PubMed Web of Science ®Google Scholar
• Wefel JS, Vardy J, Ahles T, et al. International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 2011;12(7):703–708.
   PubMed Web of Science ®Google Scholar
• Benedict RHB, Schretlen D, Groninger L, et al. Hopkins verbal learning test – revised: normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol. 1998;12(1):43–55.
   Web of Science ®Google Scholar
• Brandt J. The hopkins verbal learning test: development of a new memory test with six equivalent forms. Clin Neuropsychol. 1991;5(2):125–142.
   Google Scholar
• Benedict RHB. Brief visuospatial memory test - revised: Professional manual. Lutz, FL: Psychological Assessment Resources, Inc; 1997.
   Google Scholar
• Weschler D. WMS-III: Weschler memory scale administration and scoring manual. 3rd ed. San Antonio, Tex.: Psychological Corp; 1997.
   Google Scholar
• Maj M, D'Elia L, Satz P, World Health Organization, Division of Mental Health/Global Programme on AIDS, et al. Evaluation of two new neuropsychological tests designed to minimize cultural bias in the assessment of HIV-1 seropositive persons: a WHO study. Arch Clin Neuropsychol. 1993;8(2):123–135.
   PubMed Web of Science ®Google Scholar
• Trenerry MR, Crosson B, DeBoe J, et al. Stroop neuropsychological screening test manual. Lutz, FL: Psychological Assessment Resources; 1989.
   Google Scholar
• Benton AL, Hamsher KD, Sivan AB. Multilingual aphasia examination. Iowa City: AJA Associates; 1989.
   Google Scholar
• The Psychological Corporation, Wechsler test of adult reading. 2001. San Antonio, TX: harcourt Assessment.
   Google Scholar
• Farias SET, Mungas DM, Reed BR, et al. The measurement of everyday cognition (ECog): scale development and psychometric properties. Neuropsychology. 2008;22(4):531–544.
   PubMed Web of Science ®Google Scholar
• Hann DM, Jacobsen PB, Azzarello LM, et al. Measurement of fatigue in cancer patients: development and validation of the fatigue symptom inventory. Qual Life Res. 1998;7(4):301–310.
   PubMed Web of Science ®Google Scholar
• Radloff LS. The CES-D Scale: a self-report depression scale for research in the general population. 1977.
   Google Scholar
• Morin CM, Belleville G, Bélanger L, et al. The insomnia severity index: psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep. 2011;34(5):601–608.
   PubMed Web of Science ®Google Scholar
• Jim HSL, Hyland KA, Nelson AM, et al. Internet-assisted cognitive behavioral intervention for targeted therapy–related fatigue in chronic myeloid leukemia: results from a pilot randomized trial. Cancer. 2020;126(1):174–180.
   PubMed Web of Science ®Google Scholar
• Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: l. Erlbaum Associates; 1988.
   Google Scholar
• Jim HSL, Phillips KM, Chait S, et al. Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol. 2012;30(29):3578–3587.
   PubMed Web of Science ®Google Scholar
• Janelsins MC, Kohli S, Mohile SG, et al. An update on cancer- and chemotherapy-related cognitive dysfunction: current status. Semin Oncol. 2011;38(3):431–438.
   PubMed Web of Science ®Google Scholar
• Wefel JS, Kesler SR, Noll KR, et al. Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA Cancer J Clin. 2015;65(2):123–138.
   PubMed Web of Science ®Google Scholar
• Cagney KA, Lauderdale DS. Education, wealth, and cognitive function in later life. J Gerontol B Psychol Sci Soc Sci. 2002;57(2):P163–P172.
   PubMed Web of Science ®Google Scholar
• Janelsins MC, Kesler SR, Ahles TA, et al. Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry. 2014;26(1):102–113.
   PubMed Web of Science ®Google Scholar
• Vardy JL, Dhillon HM, Pond GR, et al. Cognitive function in patients with colorectal cancer who do and do not receive chemotherapy: a prospective, longitudinal, controlled study. J Clin Oncol. 2015;33(34):4085–4092.
   PubMed Web of Science ®Google Scholar
• Mulder SF, Bertens D, Desar IM, et al. Impairment of cognitive functioning during sunitinib or sorafenib treatment in cancer patients: a cross sectional study. BMC Cancer. 2014;14:219.
   PubMed Web of Science ®Google Scholar
• Savard J, Ganz PA. Subjective or objective measures of cognitive Functioning-What’s more important? JAMA Oncol. 2016;2(10):1263–1264.
   PubMed Web of Science ®Google Scholar
• Hutchinson AD, Hosking JR, Kichenadasse G, et al. Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev. 2012;38(7):926–934.
   PubMed Web of Science ®Google Scholar
• Kim H-J, Barsevick AM, Fang CY, et al. Common biological pathways underlying the psychoneurological symptom cluster in cancer patients. Cancer Nurs. 2012;35(6):E1–E20.
   PubMed Web of Science ®Google Scholar
• Joly F, Heutte N, Duclos B, et al. Prospective evaluation of the impact of antiangiogenic treatment on cognitive functions in metastatic renal cancer. Eur Urol Focus. 2016;2(6):642–649.
   PubMedGoogle Scholar
• Feng LR, Espina A, Saligan LN. Association of fatigue intensification with cognitive impairment during radiation therapy for prostate cancer. OCL. 2018;94(6):363–372.
   Google Scholar
• Miller AH, Ancoli-Israel S, Bower JE, et al. Neuroendocrine-Immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol. 2008;26(6):971–982.
   PubMed Web of Science ®Google Scholar
• Joly F, Lange M, Dos Santos M, et al. Long-Term fatigue and cognitive disorders in breast cancer survivors. Cancers (Basel). 2019;11(12):1896.
   PubMed Web of Science ®Google Scholar
• Goedendorp MM, Knoop H, Gielissen MFM, et al. The effects of cognitive behavioral therapy for postcancer fatigue on perceived cognitive disabilities and neuropsychological test performance. J Pain Symptom Manage. 2014;47(1):35–44.
   PubMed Web of Science ®Google Scholar
• Lange M, Licaj I, Clarisse B, et al. Cognitive complaints in cancer survivors and expectations for support: results from a web–based survey. Cancer Med. 2019;8(5):2654–2663.
   PubMed Web of Science ®Google Scholar
• Abdel-Aziz AK, Mantawy EM, Said RS, et al. The tyrosine kinase inhibitor, sunitinib malate, induces cognitive impairment in vivo via dysregulating VEGFR signaling, apoptotic and autophagic machineries. Exp Neurol. 2016;283(Pt A):129–141.
   PubMedGoogle Scholar
• Williams A, van Wijngaarden E, Seplaki C, et al. Cognitive function in chronic lymphocytic leukemia (CLL): examining effects of disease, treatment, and inflammation. J Clin Oncol. 2019;37(15_suppl):11584–11584.
   Web of Science ®Google Scholar
• WIlliams AM, van Wijngaarden E, Seplaki CL, et al. Cognitive function in patients with chronic lymphocytic leukemia: a cross-sectional study examining effects of disease and treatment. Leuk Lymphoma. 2020;61(7):1627–1635.
   PubMed Web of Science ®Google Scholar